• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Letter to the editor: the inflamed subclass predicts immunotherapy response - external validations.

作者信息

Li Binghua, Cao Yajuan, Li Yunzheng, Cheng Chunxiao, Yu Decai

机构信息

Department of Hepatobiliary Surgery, the Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, China.

Department of Hepatobiliary Surgery, the Affiliated Drum Tower Hospital, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.

出版信息

Gut. 2022 Jul 16. doi: 10.1136/gutjnl-2022-328130.

DOI:10.1136/gutjnl-2022-328130
PMID:35842234
Abstract
摘要

相似文献

1
Letter to the editor: the inflamed subclass predicts immunotherapy response - external validations.致编辑的信：炎症亚类可预测免疫治疗反应——外部验证
Gut. 2022 Jul 16. doi: 10.1136/gutjnl-2022-328130.
2
Letter to the editor: Is the intratumor steatosis a novel biomarker for predicting the efficacy of immunotherapy in hepatocellular carcinoma?
Hepatology. 2022 Dec;76(6):E131-E132. doi: 10.1002/hep.32616. Epub 2022 Jun 22.
3
Letter to the Editor: Comment on: "LI‑RADS Morphological Type Predicts Prognosis of Patients with Hepatocellular Carcinoma After Radical Resection".致编辑的信：对“LI-RADS形态学类型预测肝细胞癌根治性切除术后患者的预后”的评论
Ann Surg Oncol. 2023 Dec;30(13):8023-8024. doi: 10.1245/s10434-023-14444-w. Epub 2023 Oct 12.
4
A Novel mRNA Signature Related to Immunity to Predict Survival and Immunotherapy Response in Hepatocellular Carcinoma.一种与免疫相关的新型mRNA特征用于预测肝细胞癌的生存及免疫治疗反应
J Clin Transl Hepatol. 2022 Oct 28;10(5):925-938. doi: 10.14218/JCTH.2021.00283. Epub 2022 Feb 21.
5
Cancer-Testis Gene Expression in Hepatocellular Carcinoma: Identification of Prognostic Markers and Potential Targets for Immunotherapy.肝癌中癌-睾丸基因的表达：预后标志物的鉴定和免疫治疗的潜在靶点。
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820944274. doi: 10.1177/1533033820944274.
6
Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer.Siglec15 塑造非炎症性肿瘤微环境，并预测膀胱癌的分子亚型。
Theranostics. 2021 Jan 1;11(7):3089-3108. doi: 10.7150/thno.53649. eCollection 2021.
7
Response to the Letter to the Editor: Lung Immune Prognostic Index for Outcome Prediction to Immunotherapy in Patients With NSCLC.
J Thorac Oncol. 2019 Sep;14(9):e208. doi: 10.1016/j.jtho.2019.05.035. Epub 2019 Jun 7.
8
Clinicopathological indices to predict hepatocellular carcinoma molecular classification.预测肝细胞癌分子分类的临床病理指标。
Liver Int. 2016 Jan;36(1):108-18. doi: 10.1111/liv.12889. Epub 2015 Jun 29.
9
Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score.免疫治疗肝细胞癌患者的预后——CRAFITY 评分的建立和验证。
J Hepatol. 2022 Feb;76(2):353-363. doi: 10.1016/j.jhep.2021.09.035. Epub 2021 Oct 12.
10
Complete clinicoradiographic remission following immunotherapy treatment for an unresectable, multiply-recurrent oral verrucous carcinoma: A letter to the editor.
Oral Oncol. 2023 Nov;146:106567. doi: 10.1016/j.oraloncology.2023.106567. Epub 2023 Sep 29.

引用本文的文献

1
Integrating bulk and single cell sequencing data to identify prognostic biomarkers and drug candidates in HBV associated hepatocellular carcinoma.整合批量和单细胞测序数据以鉴定HBV相关肝细胞癌中的预后生物标志物和候选药物。
Sci Rep. 2025 Jul 18;15(1):26038. doi: 10.1038/s41598-025-10876-4.
2
Expression landscape of epigenetic genes in human hepatocellular carcinoma.人类肝细胞癌中表观遗传基因的表达图谱
J Physiol Biochem. 2025 Jun 12. doi: 10.1007/s13105-025-01095-6.
3
Stromal architecture and fibroblast subpopulations with opposing effects on outcomes in hepatocellular carcinoma.
基质结构和成纤维细胞亚群对肝细胞癌预后具有相反影响。
Cell Discov. 2025 Jan 28;11(1):1. doi: 10.1038/s41421-024-00747-z.
4
A novel molecular classification system based on the molecular feature score identifies patients sensitive to immune therapy and target therapy.一种基于分子特征评分的新型分子分类系统可识别出对免疫疗法和靶向疗法敏感的患者。
Front Immunol. 2024 Nov 26;15:1466069. doi: 10.3389/fimmu.2024.1466069. eCollection 2024.
5
The MHC-I-dependent neoantigen presentation pathway predicts response rate to PD-1/PD-L1 blockade.MHC-I依赖性新抗原呈递途径可预测对PD-1/PD-L1阻断疗法的反应率。
Biomol Biomed. 2025 Apr 26;25(6):1314-1321. doi: 10.17305/bb.2024.11069.
6
Comprehensive analysis of transcriptomic biomarkers for predicting response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma.用于预测肝细胞癌患者对阿替利珠单抗联合贝伐单抗免疫治疗反应的转录组生物标志物的综合分析
Clin Mol Hepatol. 2025 Jan;31(1):e31-e34. doi: 10.3350/cmh.2024.0628. Epub 2024 Sep 20.
7
Mitotic catastrophe heterogeneity: implications for prognosis and immunotherapy in hepatocellular carcinoma.有丝分裂灾难异质性：对肝细胞癌预后和免疫治疗的影响
Front Immunol. 2024 Jul 1;15:1409448. doi: 10.3389/fimmu.2024.1409448. eCollection 2024.
8
Prognostic hub gene CBX2 drives a cancer stem cell-like phenotype in HCC revealed by multi-omics and multi-cohorts.多组学和多队列研究揭示预后枢纽基因 CBX2 驱动 HCC 中的癌症干细胞样表型。
Aging (Albany NY). 2023 Nov 17;15(22):12817-12851. doi: 10.18632/aging.205173.